|
IN148482B
(fr)
|
1977-06-03 |
1981-03-07 |
Pfizer |
|
|
CA1114379A
(fr)
*
|
1977-11-03 |
1981-12-15 |
Pfizer Corporation |
Piperidino-phtalazines
|
|
US4370328A
(en)
|
1977-11-03 |
1983-01-25 |
Pfizer Inc. |
Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines
|
|
US5001125A
(en)
*
|
1984-03-26 |
1991-03-19 |
Janssen Pharmaceutica N.V. |
Anti-virally active pyridazinamines
|
|
EP0174464B1
(fr)
*
|
1984-09-14 |
1990-01-03 |
ASTA Pharma AG |
Benzyl-phtalazinones substitués
|
|
US4868179A
(en)
*
|
1987-04-22 |
1989-09-19 |
Cohn Jay N |
Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
|
|
US5106973A
(en)
*
|
1987-11-23 |
1992-04-21 |
Janssen Pharmaceutica N.V. |
Pyridzainamine derivatives
|
|
US4963676A
(en)
*
|
1988-02-09 |
1990-10-16 |
Georgia State University Foundation, Inc. |
Di-substituted phthalazines
|
|
JO1645B1
(en)
*
|
1989-12-26 |
1991-11-27 |
شركة جانسين فارماسوتيكا ان. في |
Pyridazine compounds are antibacterial viruses
|
|
EP0449203B1
(fr)
*
|
1990-03-30 |
1994-12-07 |
Mitsubishi Chemical Corporation |
Dérivés de 4-phénylphthalazine
|
|
US5100893A
(en)
*
|
1990-04-18 |
1992-03-31 |
Janssen Pharmaceutica N.V. |
Antipicornaviral pyridazinamines
|
|
TW279162B
(fr)
*
|
1991-09-26 |
1996-06-21 |
Mitsubishi Chem Corp |
|
|
CH683965A5
(it)
*
|
1993-02-19 |
1994-06-30 |
Limad Marketing Exp & Imp |
Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
|
|
US5716956A
(en)
*
|
1995-06-07 |
1998-02-10 |
Bearsden Bearsden Bio, Inc. |
Dihydrophthalazine antagonists of excitatory amino acid receptors
|
|
CA2275686C
(fr)
*
|
1996-12-18 |
2006-10-17 |
Neurogen Corporation |
Derives d'isoquinoleinamine et de phtalazinamine qui interagissent grace a des recepteurs du facteur liberant de la corticotropine (crf)
|
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
|
JP4673977B2
(ja)
|
1999-03-30 |
2011-04-20 |
ノバルティス アーゲー |
炎症性疾患治療用フタラジン誘導体
|
|
AR025068A1
(es)
*
|
1999-08-10 |
2002-11-06 |
Bayer Corp |
Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
|
|
US6689883B1
(en)
|
1999-09-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Substituted pyridines and pyridazines with angiogenesis inhibiting activity
|
|
CO5200835A1
(es)
*
|
1999-09-28 |
2002-09-27 |
Bayer Corp |
Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
|
|
DE19963607B4
(de)
*
|
1999-12-23 |
2005-12-15 |
Schering Ag |
Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
|
|
US7977333B2
(en)
*
|
2000-04-20 |
2011-07-12 |
Bayer Healthcare Llc |
Substituted pyridines and pyridazines with angiogenesis inhibiting activity
|
|
AR028782A1
(es)
*
|
2000-07-05 |
2003-05-21 |
Taisho Pharmaceutical Co Ltd |
Derivados heterociclicos tetrahidropiridino o piperidino
|
|
US6903101B1
(en)
|
2000-08-10 |
2005-06-07 |
Bayer Pharmaceuticals Corporation |
Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
|
|
GB0111078D0
(en)
*
|
2001-05-04 |
2001-06-27 |
Novartis Ag |
Organic compounds
|
|
US20030236259A1
(en)
*
|
2002-02-05 |
2003-12-25 |
Rolf Hohlweg |
Novel aryl- and heteroarylpiperazines
|
|
GB0223341D0
(en)
*
|
2002-10-08 |
2002-11-13 |
Groningen Acad Ziekenhuis |
Organic compounds
|
|
GB0310726D0
(en)
*
|
2003-05-09 |
2003-06-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
AU2004295058B9
(en)
|
2003-11-20 |
2011-06-30 |
Janssen Pharmaceutica N.V. |
6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
|
|
EA011211B1
(ru)
*
|
2003-11-20 |
2009-02-27 |
Янссен Фармацевтика Н. В. |
7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
|
|
EP1709012B1
(fr)
*
|
2003-12-05 |
2015-07-29 |
Janssen Pharmaceutica NV |
2-quinolinones 6-substituées et 2-quinoxalinones utilisées comme inhibiteurs de la poly(adp-ribose) polymérase
|
|
WO2006004589A2
(fr)
*
|
2004-05-08 |
2006-01-12 |
Neurogen Corporation |
Pyridazines 3-aryl-5,6-disubstituees
|
|
US8014799B2
(en)
*
|
2004-06-02 |
2011-09-06 |
Ktfreetel Co., Ltd. |
System for providing application and management service and modifying user interface and method thereof
|
|
SG154432A1
(en)
|
2004-06-30 |
2009-08-28 |
Janssen Pharmaceutica Nv |
Quinazolinedione derivatives as parp inhibitors
|
|
WO2006003150A1
(fr)
|
2004-06-30 |
2006-01-12 |
Janssen Pharmaceutica N.V. |
Derives de 2-alkyl quinazolinone substitues en tant qu'inhibiteurs de parp
|
|
JP4852540B2
(ja)
*
|
2004-06-30 |
2012-01-11 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Parp阻害剤としてのフタラジン誘導体
|
|
EP1778267A4
(fr)
*
|
2004-07-16 |
2010-01-06 |
Nitromed Inc |
Compositions et methodes associees a l'insuffisance cardiaque
|
|
US20070020330A1
(en)
*
|
2004-11-24 |
2007-01-25 |
Medpointe Healthcare Inc. |
Compositions comprising azelastine and methods of use thereof
|
|
US8758816B2
(en)
|
2004-11-24 |
2014-06-24 |
Meda Pharmaceuticals Inc. |
Compositions comprising azelastine and methods of use thereof
|
|
DK2486942T3
(en)
*
|
2004-11-24 |
2019-01-28 |
Meda Pharmaceuticals Inc |
COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT
|
|
EP2386554A1
(fr)
|
2005-07-04 |
2011-11-16 |
High Point Pharmaceuticals, LLC |
Composés actives sur le recepteur histamine H3
|
|
BRPI0707223A2
(pt)
*
|
2006-01-27 |
2011-04-26 |
Pfizer Prod Inc |
compostos de derivados de aminoftalazina
|
|
CA2634473A1
(fr)
*
|
2006-02-17 |
2007-08-30 |
Nitromed, Inc. |
Procedes utilisant des composes d'hydralazine et du dinitrate d'isosorbide ou du mononitrate d'isosorbide
|
|
AU2007254283A1
(en)
*
|
2006-05-16 |
2007-11-29 |
Nitromed, Inc. |
Solid dosage formulations of hydralazine compounds
|
|
EP2079732B9
(fr)
*
|
2006-05-29 |
2012-03-21 |
High Point Pharmaceuticals, LLC |
3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyradine, ses sels et solvates et son utilisation comme antagoniste du recepteur d'histamin h3
|
|
HRP20120346T1
(hr)
*
|
2007-03-08 |
2012-05-31 |
Janssen Pharmaceutica N.V. |
Derivati kinolinona kao parp i tank inhibitori
|
|
EP2137162B1
(fr)
|
2007-03-15 |
2018-08-01 |
Novartis AG |
Composés organiques et leurs utilisations
|
|
EP2014656A3
(fr)
*
|
2007-06-11 |
2011-08-24 |
High Point Pharmaceuticals, LLC |
Nouveaux antagonistes d'hétéocycliques h3
|
|
PL2215075T3
(pl)
*
|
2007-10-26 |
2014-04-30 |
Janssen Pharmaceutica Nv |
Pochodne chinolinonu jako inhibitory PARP
|
|
AU2009228945B2
(en)
*
|
2008-03-27 |
2013-05-02 |
Janssen Pharmaceutica Nv |
Quinazolinone derivatives as tubulin polymerization inhibitors
|
|
JP5492183B2
(ja)
|
2008-03-27 |
2014-05-14 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Parpおよびチューブリン重合阻害剤としてのテトラヒドロフェナントリジノンおよびテトラヒドロシクロペンタキノリノン
|
|
US7981892B2
(en)
*
|
2008-04-29 |
2011-07-19 |
Eli Lilly And Company |
Disubstituted phthalazine hedgehog pathway antagonists
|
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
|
PE20110433A1
(es)
*
|
2008-11-03 |
2011-07-09 |
Lilly Co Eli |
Antagonistas de la via hedgehog de ftalazina disustituida
|
|
PL2358698T3
(pl)
|
2008-11-17 |
2013-01-31 |
Lilly Co Eli |
Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
|
|
JP5518088B2
(ja)
*
|
2008-11-17 |
2014-06-11 |
イーライ リリー アンド カンパニー |
四置換ピリダジンヘッジホッグ経路アンタゴニスト
|
|
WO2016123796A1
(fr)
*
|
2015-02-06 |
2016-08-11 |
Abbvie Inc. |
Phtalazines substituées
|
|
WO2018080216A1
(fr)
*
|
2016-10-28 |
2018-05-03 |
Daewoong Pharmaceutical Co., Ltd. |
Dérivé de phénylphtalazine, sa méthode de préparation et composition pharmaceutique le comprenant
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
WO2022165173A1
(fr)
*
|
2021-01-28 |
2022-08-04 |
The Scripps Research Institute |
Composés et leur utilisation pour le traitement de troubles neurodégénératifs, dégénératifs et métaboliques
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
US20240294542A1
(en)
*
|
2021-06-05 |
2024-09-05 |
Transthera Sciences (Nanjing), Inc. |
Nlrp3 inflammasome inhibitor and application thereof
|
|
US20240391881A1
(en)
*
|
2021-09-30 |
2024-11-28 |
Origiant Pharmaceutical Co., Ltd. |
Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|